研报掘金|华泰证券:上调康方生物目标价至103.68港元 上调今明两年纯利预测

阿斯达克财经
02 Apr

4月2日|华泰证券上调对康方生物今明两年纯利预测,由7100万及6.48亿元,上调至7400万及6.56亿元,主要因公司销售、管理费用控制成效显著,并料2027年纯利14.07亿元。该行对其目标价由100.45港元上调至103.68港元,维持“买入”评级。该行认为康方生物基本面出色,核心产品纳入医保且新适应症逐步获批,料可实现销售增长,且核心管线全球潜力强劲,多款新药进入临床阶段,筑牢发展根基。

新闻来源 (不包括新闻图片): 格隆汇

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10